Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Organ-specific terpenoid responses in Tanacetum vulgare are chemotype-dependent.

Plant biology (Stuttgart, Germany)·2026

Same author

The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR)--Critical review facing the 20 anniversary.

Multiple sclerosis and related disorders·2022

Same author

Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials.

Contemporary clinical trials·2020

Same author

Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?

European journal of neurology·2017

Same author

The relationship of age with the clinical phenotype in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2016

Same author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2015

Search research articles

Related Experiment Video

Updated: May 29, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Age and disability accumulation in multiple sclerosis.

A Scalfari¹, A Neuhaus, M Daumer

¹University Department of Clinical Neurology, Level 3, West Wing, John Radcliffe Hospital, Oxford, UK, OX3 9DU. george.ebers@clneuro.ox.ac.uk

|September 16, 2011

Summary

This summary is machine-generated.

Age at multiple sclerosis (MS) onset influences disability progression, primarily by affecting the likelihood and timing of developing secondary progressive MS. The disease course itself is less impacted by age.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: May 29, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

Neurology
Clinical Epidemiology

Background:

Multiple sclerosis (MS) prognosis is influenced by various factors, including disease course and patient characteristics.
Understanding the role of age in long-term disability accumulation is crucial for predicting MS outcomes.

Purpose of the Study:

To investigate whether age serves as a prognostic factor for long-term disability accumulation in multiple sclerosis.
To determine the specific impact of age at different disease stages on disability progression.

Main Methods:

Kaplan-Meier analysis and binary logistic regression were employed.
The study analyzed data from 1,023 patients in the London, Ontario MS database.
Key variables included age at disease onset, age at progression onset, and current age, assessed against severe disability levels (Disability Status Scale [DSS] 6-8-10).

Main Results:

Older age at the onset of the relapsing-remitting (RR) phase correlated with a higher risk of advanced disability (DSS scores).
This association was independent of disease duration and early relapse frequency but linked to an increased risk of conversion to secondary progressive (SP) MS.
Onset at 40 or 50 years significantly increased the risk of developing SP MS compared to onset at 20 years. Younger age at SP MS conversion predicted shorter times to severe disability.
The progressive course of MS was minimally affected by age at SP onset and unaffected by age at RR onset.

Conclusions:

The development of SP MS is the primary determinant of long-term prognosis in MS, irrespective of disease duration or early relapse rates.
Age independently influences disability progression by altering the probability and timing of SP MS onset.
Age has a limited effect on the progression rate of established SP MS.